Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study

Publisher： Karger

E-ISSN： 2296-5262|36|3|95-100

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.36, Iss.3, 2013-02, pp. : 95-100

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4325-4332

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

By  

CANCER, Vol. 120, Iss. 11, 2014-06 ,pp. : 1647-1655

John Wiley & Sons Inc

Access to resources Recommend Favorite

Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: A Review of Recent Clinical Trials

By  

Reviews on Recent Clinical Trials, Vol. 2, Iss. 2, 2007-05 ,pp. : 117-120

Bentham Science Publishers

Access to resources Recommend Favorite

The role of vascular epithelial growth factor receptor–tyrosine kinase inhibitors in the treatment of advanced breast cancer: a meta-analysis of 12 randomized controlled trials

By Li Jianwen   Huang Shengchao   Zheng Wanting   Ding Hongfei   Zhang Yuanqi   Huang Shuichuan   Zhang Zhi   Chen Baoying   Liang Zhongzeng   He Gan   Xiao Xiongsheng   Li Siyi   Xu Tuo   Chen Xiaodong  

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1691-1699

Informa Healthcare

Access to resources Recommend Favorite

Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease

By  

Case Reports in Oncology, Vol. 4, Iss. 3, 2011-09 ,pp. : 470-474

Karger

Access to resources Recommend Favorite